摘要
目的:观察多西他赛联合氟尿嘧啶治疗进展期胃癌的疗效及安全性。方法:84例进展期胃癌患者随机分为A、B两组42例。A组采用多西他赛联合氟尿嘧啶化疗,B组采用多西他赛联合替吉奥化疗。两组患者均以21 d为1个周期,至少化疗2个周期。观察两组患者治疗后近期临床疗效、患者体能状态改善情况以及药品不良反应发生情况。结果:两组患者总有效率比较差异无统计学意义(P>0.05),但A组体能状态改善率(40.48%)显著高于B组(20.24%),差异有统计学意义(P<0.05)。A组血小板下降和中性粒细胞下降发生率显著低于B组(P<0.05)。结论:多西他赛联合氟尿嘧啶治疗进展期胃癌临床疗效显著,能显著改善患者体能状态,且不良反应相对较少。
Objective：To observe the clinical efficacy and safety of docetaxel combined with 5-fluorouracil in the treatment of pa-tients with advanced gastric cancer. Methods：Totally 84 cases of gastric cancer patients were randomly divided into group A and group B with 42 ones in each. Group A was given chemotherapy of docetaxel combined with 5-fluorouracil, and group B was treated with chemotherapy of Tegafur combined with docetaxel. One cycle was 21 days, and the patients were given at least two cycles of chemother-apy. The recent clinical curative effect, physical state improvement and adverse reactions in the two groups after the treatment were ob-served. Results：The total effective rate of the two groups showed no significant difference （P〈0. 05）, however, the physical state improvement rate of group A （40. 48%） was significantly higher than that of group B （20. 24%） with statistical significance （P〈0. 05）. The incidence of thrombocytopenia and neutropenia decrease of group A was significantly lower than that of group B with statis-tically significant difference （P〈0. 05）. Conclusion：The treatment of advanced gastric cancer patients with docetaxel combined with 5-fluorouracil can achieve significant clinical efficacy with relatively mild toxicity,it can significantly improve the physical state of pa-tient.
出处
《中国药师》
CAS
2015年第5期804-806,共3页
China Pharmacist
关键词
多西他赛
氟尿嘧啶
进展期胃癌
临床疗效
Docetaxel
Fluorouracil
Advanced gastric cancer
Clinical efficacy
